🎉 M&A multiples are live!
Check it out!

Adaptimmune Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Adaptimmune Therapeutics and similar public comparables like Galapagos, Benevolent AI, and Vivoryon Therapeutics.

Adaptimmune Therapeutics Overview

About Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.


Founded

2014

HQ

United States of America
Employees

506

Website

adaptimmune.com

Financials

LTM Revenue $138M

LTM EBITDA -$79.4M

EV

-$17.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Adaptimmune Therapeutics Financials

Adaptimmune Therapeutics has a last 12-month revenue of $138M and a last 12-month EBITDA of -$79.4M.

In the most recent fiscal year, Adaptimmune Therapeutics achieved revenue of $178M and an EBITDA of -$52.7M.

Adaptimmune Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Adaptimmune Therapeutics valuation multiples based on analyst estimates

Adaptimmune Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $60.3M $178M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$128M -$52.7M XXX XXX XXX
EBITDA Margin -213% -30% XXX XXX XXX
Net Profit -$165M -$114M XXX XXX XXX
Net Margin -274% -64% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Adaptimmune Therapeutics Stock Performance

As of April 15, 2025, Adaptimmune Therapeutics's stock price is $0.

Adaptimmune Therapeutics has current market cap of $60.2M, and EV of -$17.2M.

See Adaptimmune Therapeutics trading valuation data

Adaptimmune Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$17.2M $60.2M XXX XXX XXX XXX $-0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Adaptimmune Therapeutics Valuation Multiples

As of April 15, 2025, Adaptimmune Therapeutics has market cap of $60.2M and EV of -$17.2M.

Adaptimmune Therapeutics's trades at -0.1x LTM EV/Revenue multiple, and 0.2x LTM EBITDA.

Analysts estimate Adaptimmune Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Adaptimmune Therapeutics and 10K+ public comps

Adaptimmune Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$17.2M XXX XXX XXX
EV/Revenue -0.1x XXX XXX XXX
EV/EBITDA 0.3x XXX XXX XXX
P/E -0.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Adaptimmune Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Adaptimmune Therapeutics Valuation Multiples

Adaptimmune Therapeutics's NTM/LTM revenue growth is -65%

Adaptimmune Therapeutics's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.5M for the same period.

Over next 12 months, Adaptimmune Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Adaptimmune Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Adaptimmune Therapeutics and other 10K+ public comps

Adaptimmune Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 195% XXX XXX XXX XXX
EBITDA Margin -30% XXX XXX XXX XXX
EBITDA Growth -59% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -95% XXX XXX XXX XXX
Revenue per Employee $0.4M XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue 0% XXX XXX XXX XXX
G&A Expenses to Revenue 45% XXX XXX XXX XXX
R&D Expenses to Revenue 84% XXX XXX XXX XXX
Opex to Revenue 129% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Adaptimmune Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Adaptimmune Therapeutics M&A and Investment Activity

Adaptimmune Therapeutics acquired  XXX companies to date.

Last acquisition by Adaptimmune Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Adaptimmune Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Adaptimmune Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Adaptimmune Therapeutics

When was Adaptimmune Therapeutics founded? Adaptimmune Therapeutics was founded in 2014.
Where is Adaptimmune Therapeutics headquartered? Adaptimmune Therapeutics is headquartered in United States of America.
How many employees does Adaptimmune Therapeutics have? As of today, Adaptimmune Therapeutics has 506 employees.
Who is the CEO of Adaptimmune Therapeutics? Adaptimmune Therapeutics's CEO is Mr. Adrian Rawcliffe.
Is Adaptimmune Therapeutics publicy listed? Yes, Adaptimmune Therapeutics is a public company listed on NAS.
What is the stock symbol of Adaptimmune Therapeutics? Adaptimmune Therapeutics trades under ADAP ticker.
When did Adaptimmune Therapeutics go public? Adaptimmune Therapeutics went public in 2015.
Who are competitors of Adaptimmune Therapeutics? Similar companies to Adaptimmune Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Adaptimmune Therapeutics? Adaptimmune Therapeutics's current market cap is $60.2M
What is the current revenue of Adaptimmune Therapeutics? Adaptimmune Therapeutics's last 12-month revenue is $138M.
What is the current EBITDA of Adaptimmune Therapeutics? Adaptimmune Therapeutics's last 12-month EBITDA is -$79.4M.
What is the current EV/Revenue multiple of Adaptimmune Therapeutics? Current revenue multiple of Adaptimmune Therapeutics is -0.1x.
What is the current EV/EBITDA multiple of Adaptimmune Therapeutics? Current EBITDA multiple of Adaptimmune Therapeutics is 0.2x.
What is the current revenue growth of Adaptimmune Therapeutics? Adaptimmune Therapeutics revenue growth between 2023 and 2024 was 195%.
Is Adaptimmune Therapeutics profitable? Yes, Adaptimmune Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.